ACAD
32.34
+0.46
+1.44%
AEMD
0.27
+0.01
+4.25%
APRI
1.22
0.00
0.00%
ARNA
4.62
+0.07
+1.43%
ATEC
1.33
-0.04
-2.92%
CFN
59.73
-0.04
-0.07%
CNAT
5.76
+0.42
+7.83%
CRXM
0.2
0.00
-1.00%
CYTX
0.48
+0.00
+0.92%
DXCM
62.42
+4.48
+7.73%
GNMK
13.22
+0.07
+0.53%
HALO
14.52
+0.65
+4.69%
ILMN
200.31
+3.15
+1.60%
INNV
0.23
-0.02
-9.96%
INO
8.66
+0.05
+0.58%
ISCO
0.06
0.00
0.00%
ISIS
72.69
+1.41
+1.98%
LGND
56.49
+1.82
+3.33%
LPTN
2.9
-0.06
-2.03%
MBVX
1.1
-0.04
-3.51%
MEIP
3.72
+0.03
+0.81%
MNOV
3.59
+0.04
+1.13%
MRTX
19.82
+0.55
+2.85%
MSTX
0.46
-0.01
-3.15%
NBIX
33.05
+1.35
+4.26%
NUVA
47
+0.24
+0.51%
ONCS
0.4
0.00
-0.25%
ONVO
6.49
+0.17
+2.69%
OREX
5.54
+0.13
+2.40%
OTIC
30.86
-2.07
-6.29%
QDEL
24.78
+0.46
+1.89%
RCPT
114.75
+4.65
+4.22%
RGLS
19.16
+0.62
+3.34%
RMD
67.12
+1.88
+2.88%
SCIE
0.01
0.00
0.00%
SPHS
0.45
-0.01
-1.70%
SRNE
10.4
+0.43
+4.31%
TROV
5.84
+0.04
+0.69%
VICL
1.03
-0.01
-0.96%
VOLC
17.97
+0.01
+0.03%
ZGNX
1.34
+0.06
+4.68%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Taxus Cardium Elects Three New Board Members Including PRC Strategic Investor Jiayue Zhang, John Wallace, U.S. Equity Trading Services Executive, And Wei-Wei Zhang, International Gene Therapy Pioneer

January 15, 2015 – 7:00 am | Edit Post
Taxus Cardium Elects Three New Board Members Including PRC Strategic Investor Jiayue Zhang, John Wallace, U.S. Equity Trading Services Executive, And Wei-Wei Zhang, International Gene Therapy Pioneer

SAN DIEGO, Jan. 15, 2015 /PRNewswire/ — Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today announced the election of the following three new directors: Mr. Jiayue Zhang, President of Shanxi Taxus Pharmaceuticals Co. Ltd. (Shanxi Taxus) and Shenzhen Frontsea Taxus Industry Capital Management, Mr. John F. Wallace, President of Philadelphia Financial Services LLC and former Chairman of the Philadelphia Stock Exchange, and Wei-Wei Zhang, M.D., Ph.D. an international pioneer in the research and commercialization of gene-based therapeutics, as new members of the Company’s Board of Directors.

The Company reported that, following a strategic investment by China-based Shanxi Taxus, and consistent with strategic and collaboration and funding agreement, Messrs. Jiayue Zhang and John Wallace were elected to the Company’s Board of Directors.  As of January 8, 2015, Shanxi Taxus beneficially owned approximately 3.5 million shares of the Company’s common stock, or 27.5% of the Company’s currently outstanding common stock on a primary basis.

Mr. Jiayue Zhang is President of Shanxi Taxus Pharmaceuticals Co. Ltd. and Shenzhen Frontsea Taxus Industry Capital Management, which are headquartered in Jinzhong City, Shanxi Providence, China. Shanxi Taxus is focused on the natural resource cultivation and manufacture of paclitaxel as well as other lines of business including natural resource management, retail pharmacy and healthcare product manufacturing.  Mr. Zhang also has interests in banking and finance as well as a developing private equity arm. In connection with his investment, Mr. Zhang has also been appointed as Executive Chairman of the Company’s Board of Directors.

Mr. John Wallace is an experienced financial and equity trading services executive. He served as Chairman of the Philadelphia Stock Exchange (PHLX) until its acquisition by NASDAQ, and is currently President of Philadelphia Financial Services LLC.  He has been associated with the PHLX since 1964, and during his years of expertise in trading and investment matters he has been an advisor to numerous companies and governments, including in the People’s Republic of China.

Dr. Wei-Wei Zhang is currently Managing Director of Adventin, Inc. a biotechnology services business, and he has played an important role in the discovery, research and commercialization of the first gene therapeutic Gendicine (Adp53) approved by a major world health regulatory authority (the SFDA of the People’s Republic of China) for the treatment of certain forms of cancer. Dr. Zhang has co-founded and led other biotechnology companies in the United States and PRC including Introgen Therapeutics, Shenzhen SBiono Gene Tech, GenStar Therapeutics, GenWay Biotech, Zhuhai Bioinforbody, Adventin, Acrotics and eBioCenter. Prior he was director of molecular biology, a gene therapy unit of Baxter Healthcare.  

Consistent with the Company’s Charter and By-laws, Mr. Jiayue Zhang has been elected as a Class I Director, and Mr. Wallace as a Class III Director.  In addition, the Board also elected Dr. Wei-Wei Zhang to the Board as a Class III Director.  Directors are elected to one of three classes, each of which has a three year term.  Class I director terms expire in 2016, Class II terms expire in 2017, and Class III directors currently have terms that will expire in 2015. 

The Company also reported that Dr. Tyler Dylan-Hyde, who is joining a European-based venture in the field of Crispr/Cas gene editing, will continue on the Company’s Board of Directors as a Class II Director.

Mr. Jiayue Zhang, President of Shanxi Taxus, stated that “this strategic investment collaboration reflects our interest in expanding into new and highly innovative technology-driven medical opportunities and advanced regenerative therapeutics. We are initially focused on the commercialization of Cardium’s FDA-cleared Excellagen product into People’s Republic of China, and welcome an opportunity to further support the clinical and commercial development of the breakthrough therapeutic Generx [Ad5FGF-4] product candidate for China and potentially other international markets.”

“The strategic collaboration with Shanxi Taxus is another important step forward to further support our plan to clinical develop and process engineer Cardium’s Generx product candidate to be the first universally affordable, easy use and accessible angiogenic gene therapy for patients with Cardiac Microvascular insufficiency potentially for millions with heart disease on a worldwide basis. We are very pleased to welcome Jiayue Zhang, John Wallace and Wei-Wei Zhang to the Company’s Board of Directors, and appreciate Tyler Dylan-Hyde’s continuing involvement with the Company as we move forward. They all share our vision to internationally develop a new generation of bio-therapeutics for global markets,” noted Christopher J. Reinhard, Chief Executive of Cardium Therapeutics.

Taxus Cardium Pharmaceuticals Group

Taxus Cardium Pharmaceuticals Group Inc. is a holding company that operates Cardium Therapeutics, a development stage advanced regenerative therapeutics company focused on the late-stage clinical and commercial development of regenerative medicine therapeutics including: (1) Angionetics, a business unit focused on the clinical and commercialization of Generx®, an interventional cardiology, angiogenic gene therapy product candidate designed for the potential treatment of patients with cardiac microvascular insufficiency and myocardial ischemia due to advanced coronary artery disease; and (2) Activation Therapeutics, a business unit focused on the commercialization of Excellagen®, an FDA-cleared flowable dermal matrix designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has additional potential tissue regeneration applications based on stem cells and other biologics (www.excellagen.com). In November 2014, the Company reported the formation of Angionetics and Activation Therapeutics to facilitate the independent monetization of Generx and Excellagen.  For more information about Taxus Cardium, visit the Company’s website www.cardiumthx.com, and for access to the Generx 2014 BIO International presentation visit http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2015 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics®, Generx®, Cardionovo®, Tissue Repair™, Excellagen®, Excellarate™, Genedexa™, and LifeAgain™, are trademarks of Cardium Therapeutics, Inc., Tissue Repair Company or LifeAgain Insurance Solutions Inc. Other trademarks belong to their respective owners.

Logo – http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO

 

SOURCE Taxus Cardium Pharmaceutical Group (CRXM)

Qualcomm-Novartis Deal Portends Wave of Clinical Trial Innovation

January 14, 2015 – 11:49 pm | Edit Post
Qualcomm-Novartis Deal Portends Wave of Clinical Trial Innovation

The significance of a deal announced last week during the 2015 International CES in Las Vegas went largely unnoticed amid the hubbub of the world’s biggest consumer technology show, packed as it was…

[[Click headline to continue reading.]]

Qualcomm-Novartis Deal Portends Wave of Clinical Trial Innovation

January 14, 2015 – 11:49 pm | Edit Post

The significance of a deal announced last week during the 2015 International CES in Las Vegas went largely unnoticed amid the hubbub of the world’s biggest consumer technology show, packed as it was…

[[Click headline to continue reading.]]

Qualcomm-Novartis Deal Portends Wave of Clinical Trial Innovation

January 14, 2015 – 11:49 pm | Edit Post

The significance of a deal announced last week during the 2015 International CES in Las Vegas went largely unnoticed amid the hubbub of the world’s biggest consumer technology show, packed as it was…

[[Click headline to continue reading.]]

Qualcomm-Novartis Deal Portends Wave of Clinical Trial Innovation

January 14, 2015 – 11:49 pm | Edit Post

The significance of a deal announced last week during the 2015 International CES in Las Vegas went largely unnoticed amid the hubbub of the world’s biggest consumer technology show, packed as it was…

[[Click headline to continue reading.]]

Resverlogix Presents at Biotech Showcase During JP Morgan Week

January 14, 2015 – 6:00 pm | Edit Post
Resverlogix Presents at Biotech Showcase During JP Morgan Week

SAN FRANCISCO, CA, Jan. 14, 2015 /PRNewswire/ – Resverlogix Corp. (TSX:RVX) (the “Company”) today announced that Donald McCaffrey, president and chief executive officer presented at the 7th Annual Biotech Showcase Conference 2015 during JP Morgan week. The presentation can be accessed via the following link: http://edge.media-server.com/m/p/5wz2z9gn

Mr. McCaffrey was excited to share developments of the Company’s proposed new phase 3 clinical trial BETONMACE. “This trial represents an unprecedented opportunity to reduce major adverse coronary events “MACE” in patients with diabetes. RVX-208 is the only selective BET-Bromodomain inhibitor in clinical trials to reduce the risk of death by cardiac events in patients with CVD and diabetes.”

About RVX-208

RVX-208 is a first-in-class, small molecule selective BET bromodomain inhibitor. BET-Bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes either on or off, returning them to a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with important benefits for patients with disease such as cardiovascular disease, diabetes mellitus, Alzheimer’s disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with diabetes mellitus and low HDL.

About Resverlogix

Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer’s disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix’s common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of cardiovascular disease, Alzheimer’s disease, peripheral artery disease and chronic kidney disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Company Contacts:

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: don@resverlogix.com            

Sarah Zapotichny
Director, Investor Relations & Corporate Communications
Resverlogix Corp.
Phone: 403-254-9252
Email: sarah@resverlogix.com

Media:

Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners, LLC
Phone: 212 845 4251
Phone: 212-845-4272
Email: tony.russo@russopartnersllc.com
Email: matt.middleman@russopartnersllc.com

SOURCE Resverlogix Corp.

Genentech Strikes DNA Sequencing Deal With Genome Pioneer

January 14, 2015 – 5:00 pm | Edit Post

Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of SamplesLA JOLLA, Calif., Jan. 14, 2015 /PRNewswire/ — Human Longevity, Inc. (HLI), the human health information technology and health care company, today announced a multi-year…

Adamis Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Exercise Of Over-Allotment Option In Full

January 14, 2015 – 5:00 pm | Edit Post

SAN DIEGO, Jan. 14, 2015 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical…

Temporary Tattoo Offers Needle-Free Way To Monitor Glucose Levels, University of California, San Diego (UCSD) Study

January 14, 2015 – 5:00 pm | Edit Post

Nanoengineers at the University of California, San Diego have tested a temporary tattoo that both extracts and measures the level of glucose in the fluid in between skin cells. This first-ever example of the flexible, easy-to-wear device could be a pro…

Auspex Pharmaceuticals Receives FDA Orphan Drug Designation Of SD-809 For Treatment Of Tourette Syndrome In The Pediatric Population

January 14, 2015 – 5:00 pm | Edit Post

LA JOLLA, Calif., Jan. 14, 2015 (GLOBE NEWSWIRE) — Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that th…